The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin’s lymphoma (NCT00796731).
Bertrand Coiffier
Consultant or Advisory Role - Sanofi ; Sanofi
Honoraria - Sanofi ; Sanofi
Franck Morschhauser
Honoraria - Sanofi ; Sanofi
Jehan Dupuis
No relevant relationships to disclose
Corinne Haioun
No relevant relationships to disclose
Fabrice Laine
No relevant relationships to disclose
Roch Houot
No relevant relationships to disclose
Herve Tilly
No relevant relationships to disclose
Oana Brehar
No relevant relationships to disclose
John M. Lambert
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Nathalie Fagniez
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Sandrine Payrard
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Vincent Ribrag
No relevant relationships to disclose